NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

About this update from Newamsterdam Pharma Company N.v.

NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the at the American College of Cardiology Annual Scientific Session (ACC.26), taking place on March 28-30 in New Orleans, Louisiana. Presentation details are as follows: Presentation Title: CETP Inhibition with Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results from the BROADWAY Trial Session Title: 1069: Next-Generation Lipid Treatment OptionsDigital Poster Presentation Date and Time: Saturday, March 28, 2026, 3:30 - 3:37 PM CDT Presenter: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam PharmaLocation: Moderated Poster Theater 06, Posters, Hall E Presentation Title: Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis Session Title: 1084: Evolving Non-Statin TherapiesDigital Poster Presentation Date and Time: Sunday, March 29, 2026, 10:18 - 10:25 AM CDT Presenter: Adam Nelson, Ph.D.Location: Moderated Poster Theater 05, Posters, Hall E Presentation Title: Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles Session Title: 1180: Linking Lipid Metrics to CVD RisksDigital Poster Presentation Date and Time: Monday, March 30, 2026, 11:00 - 11:07 AM CDT Presenter: Floriaan Schmidt, Ph.D.Location: Moderated Poster Theater 05, Posters, Hall E About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of...

View stock analysis, news, and events for Newamsterdam Pharma Company N.v.